Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release shortage
Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release is currently listed in shortage by the FDA. The FDA lists 2 affected products. This page was last refreshed from FDA data on Sep 23, 2026.
Amneal Pharmaceuticals is stopping its donepezil / memantine extended-release capsules, and this change may be permanent. Other makers — including those supplying Namzaric (memantine / donepezil) capsules in multiple strengths — have not reported a shortage.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Jun 15, 2026Currently in shortage2 of 2 products affected.
-
Jun 15, 2026First reported to the FDA2 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Amneal Pharmaceuticals 📞 866-525-7270 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Donepezil Hydrochloride; Memantine Hydrochloride, Capsule, Extended Release, 10 mg; 14 mg (NDC 69238-1248-3) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Donepezil Hydrochloride; Memantine Hydrochloride, Capsule, Extended Release, 10 mg; 28 mg (NDC 69238-1247-3) | — | — | Discontinuation of the manufacture of the drug | — |
These rows are manufacturer reports to the FDA for Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release? options further down this page.
Why is Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release in shortage?
Amneal Pharmaceuticals has reported to the FDA that they are permanently stopping the manufacturing of their extended-release capsules of this combination medication — both the 10 mg/14 mg strength and the 10 mg/28 mg strength. This isn't a temporary delay or a short-term supply issue; it's a full discontinuation of these specific products from this particular manufacturer.
No specific reason was shared publicly for why Amneal made this decision. It's worth knowing that this report only reflects what Amneal has filed with the FDA — it speaks only to their products and does not mean this combination medication is gone entirely from the market.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release?
The combination medicine donepezil and memantine (an extended-release capsule) is currently on the FDA shortage list. I know this news can feel unsettling, so let me walk you through what it means for you.
This report covers the two strengths that combine 10 mg donepezil with either 14 mg or 28 mg memantine. Neither strength has an available source from the manufacturer that filed this report (Amneal Pharmaceuticals). The reason given is that this maker is discontinuing the product. Because this is listed as a discontinuation rather than a temporary delay, this particular supply may not return — so a conversation with your prescriber is the right next step. Keep in mind this report reflects only one manufacturer; the same medicine is still made by other companies.
Here is what I suggest, in order:
- Do not stop, skip, or change your doses on your own.
- Ask your pharmacy to check wholesalers and other manufacturers — the same donepezil-memantine combination is also made by companies such as Macleods, ANI, Vitruvias, AvKARE, and others, though it may not be in local stock right away.
- If your exact product cannot be found, ask your prescriber or pharmacist about a suitable option.
Manufacturer contact numbers are listed on this page for reference, though your pharmacy usually handles those calls. This is general national information and may not match your local pharmacy's stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Namzaric | MEMANTINE HYDROCHLORIDE 7 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1 | Capsule · Oral | Allergan, Inc. | 00456-1207-30 |
| Namzaric | MEMANTINE HYDROCHLORIDE 14 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1 | Capsule · Oral | Allergan, Inc. | 00456-1214-30 |
| Namzaric | MEMANTINE HYDROCHLORIDE 21 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1 | Capsule · Oral | Allergan, Inc. | 00456-1221-30 |
| Namzaric | MEMANTINE HYDROCHLORIDE 28 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1 | Capsule · Oral | Allergan, Inc. | 00456-1228-30 |
| Memantine And Donepezil | MEMANTINE HYDROCHLORIDE 14 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1 | Capsule, Extended Release · Oral | Macleods Pharmaceuticals Limited | 33342-0312-07 |
| Memantine And Donepezil | MEMANTINE HYDROCHLORIDE 28 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1 | Capsule, Extended Release · Oral | Macleods Pharmaceuticals Limited | 33342-0313-07 |
| Memantine And Donepezil Hydrochlorides | MEMANTINE HYDROCHLORIDE 21 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1 | Capsule, Extended Release · Oral | ANI Pharmaceuticals, Inc. | 62559-0207-30 |
| Memantine And Donepezil Hydrochlorides Extended-Release | MEMANTINE HYDROCHLORIDE 28 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1 | Capsule, Extended Release · Oral | Amneal Pharmaceuticals NY LLC | 69238-1247-09 |
| Memantine And Donepezil Hydrochlorides Extended-Release | MEMANTINE HYDROCHLORIDE 14 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1 | Capsule, Extended Release · Oral | Amneal Pharmaceuticals NY LLC | 69238-1248-09 |
| Memantine Hydrochloride And Donepezil Hydrochloride | MEMANTINE HYDROCHLORIDE 14 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1 | Capsule, Extended Release · Oral | Vitruvias Therapeutics, Inc. | 69680-0183-30 |
| Memantine Hydrochloride And Donepezil Hydrochloride | MEMANTINE HYDROCHLORIDE 28 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1 | Capsule, Extended Release · Oral | Vitruvias Therapeutics, Inc. | 69680-0185-30 |
| Memantine And Donepezil Hydrochlorides Extended-Release | MEMANTINE HYDROCHLORIDE 28 mg/1; DONEPEZIL HYDROCHLORIDE 10 mg/1 | Capsule, Extended Release · Oral | AvKARE | 73190-0004-30 |
Therapeutic equivalents & pricing 9 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Memantine and Donepezil 14 mg/1; 10 mg | Macleods | 30 capsules | $7.335 | AB | Availability likely |
| Memantine and Donepezil Hydrochlorides Extended-release 14 mg/1; 10 mg | Amneal | 30 capsules | $7.335 | AB | Availability likely |
| memantine hydrochloride and donepezil hydrochloride 14 mg/1; 10 mg | Vitruvias | 30 capsules | $7.335 | AB | Availability likely |
| Memantine and Donepezil 28 mg/1; 10 mg | Macleods | 30 capsules | $9.448 | AB | Availability likely |
| Memantine and Donepezil Hydrochlorides Extended-release 28 mg/1; 10 mg | Amneal | 30 capsules | $9.448 | AB | Availability likely |
| memantine hydrochloride and donepezil hydrochloride 28 mg/1; 10 mg | Vitruvias | 30 capsules | $9.448 | AB | Availability likely |
| Namzaric 14 mg/1; 10 mg | Allergan, | 10 capsules | — | AB | Discontinued |
| Namzaric 28 mg/1; 10 mg | Allergan, | 10 capsules | — | AB | Discontinued |
| Memantine and Donepezil Hydrochlorides Extended-release 28 mg/1; 10 mg | AvKARE | 30 capsules | — | AB | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Identity & classification
Where does this data come from?
Other neurology shortages
Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release shortage FAQs
Is Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release in shortage?
Which products are affected?
When will Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release be available again?
Can I still get Donepezil Hydrochloride; Memantine Hydrochloride somewhere?
What should I do if I take Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release?
Still have a question about the Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release shortage?
Ask a pharmacist about this shortage →View Donepezil Hydrochloride; Memantine Hydro... on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.